Related Experiment Video
Updated: Aug 12, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Circ_0001312 Silencing Suppresses Doxorubicin-Induced Cardiotoxicity via MiR-409-3p/HMGB1 Axis
Xiaochun Hu1, Wang Liao1, Lifeng Teng1
1Department of Cardiovascular Medicine, Hainan Provincial People's Hospital.
Abstract:
Doxorubicin (DOX) is a potent cytotoxic chemotherapeutic agent limited in clinical application owing to its cumulative and irreversible cardiotoxicity. Circ_0001312 is highly expressed in patients with heart failure. However, it is still unclear whether circ_0001312 plays any roles in DOX-induced cardiotoxicity.Human AC16 cardiomyocytes in functional group were stimulated with DOX. The levels of genes and proteins were detected by qRT-PCR and western blotting. The proliferation, apoptosis, as well as inflammatory and oxidative injury in cardiomyocytes were investigated. Dual-luciferase reporter, RNA immunoprecipitation, and pull-down assays were utilized to confirm the binding between miR-409-3p and circ_0001312 or HMGB1 (high-mobility group box 1). Exosomes were isolated by using the commercial kit and identified by transmission electron microscopy (TEM) and nanoparticle-tracking analysis (NTA).DOX impaired cardiomyocyte proliferation and induced apoptotic, inflammatory, and oxidative injury in cells. Furthermore, it promoted circ_0001312 expression, and the knockdown of circ_0001312 could reverse DOX-evoked cardiomyocyte injury. In terms of mechanics, circ_0001312 bound competitively to miR-409-3p to up-regulate HMGB1, which was a target of miR-409-3p. DOX decreased the miR-409-3p but increased the HMGB1 expression in cardiomyocytes. Functionally, miR-409-3p inhibition attenuated the protective action of circ_0001312 silencing on cardiomyocytes under DOX treatment. Moreover, miR-409-3p could abate DOX-evoked apoptosis, and inflammation and oxidative stress in cardiomyocytes, and these effects were counteracted by HMGB1 overexpression. In addition, circ_0001312 was secreted by exosomes and could be transmitted via exosomes.Circ_0001312 reversed the cytotoxic effects mediated by DOX on cardiomyocytes via the miR-409-3p/HMGB1 axis. Besides, it was released to the extracellular space by exosomes.
Insights
Circular RNA circ_0001312 protects heart cells from chemotherapy drug Doxorubicin (DOX) damage. It acts through the miR-409-3p/HMGB1 pathway and is released via exosomes, offering a potential therapeutic target for cardiotoxicity.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Doxorubicin (DOX) chemotherapy causes cardiotoxicity, limiting its use.
- Circ_0001312 is upregulated in heart failure, but its role in DOX cardiotoxicity is unknown.
Purpose of the Study:
- To investigate the role of circ_0001312 in Doxorubicin-induced cardiotoxicity.
- To elucidate the underlying molecular mechanism involving miR-409-3p and HMGB1.
Main Methods:
- Human AC16 cardiomyocytes were treated with DOX.
- Gene and protein expression analyzed by qRT-PCR and Western blotting.
- Cell proliferation, apoptosis, inflammation, and oxidative injury assessed.
- Molecular interactions confirmed via dual-luciferase, RIP, and pull-down assays.
- Exosome isolation and characterization performed.
Main Results:
- DOX impaired cardiomyocyte proliferation and induced injury.
- Circ_0001312 expression increased with DOX; its knockdown protected cardiomyocytes.
- Circ_0001312 competitively binds miR-409-3p, upregulating HMGB1.
- DOX decreased miR-409-3p and increased HMGB1.
- miR-409-3p inhibition counteracted circ_0001312 knockdown benefits.
- HMGB1 overexpression reversed miR-409-3p's protective effects.
- Circ_0001312 is secreted and transmitted via exosomes.
Conclusions:
- Circ_0001312 protects cardiomyocytes against DOX-induced toxicity via the miR-409-3p/HMGB1 axis.
- Exosomal release of circ_0001312 suggests a role in intercellular communication in cardiotoxicity.
- Circ_0001312 represents a potential therapeutic target for mitigating DOX cardiotoxicity.
Related Concept Videos
MicroRNAs
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

